Retinoic‐Acid‐Derived Ionizable Lipids Enable Spleen‐Selective Antigen Expression for mRNA Cancer Vaccination
Academic source · Angewandte Chemie International Edition
Source published:
Site published: 2026-11-03 · Updated: 2026-11-03
This source is linked automatically. Choose a question to get started.
What the paper reports
A 40-member retinoic-acid-derived ionizable-lipid library yielded AT4-13CRA particles with preferential functional expression in splenic antigen-presenting cells. Researchers linked delivery to altered protein coronas and reduced lysosomal retention. An ovalbumin vaccination model showed stronger antigen-specific immunity and prophylactic tumor protection. The artificial antigen and challenge setting limit direct extrapolation to established human cancers.
Why this paper is included
Supports hydrophobic-domain engineering for APC-centered vaccination; model-antigen prophylactic protection does not establish efficacy against established patient tumors.
The interpretation above is analysis, not a conclusion attributed to the original source.
Read the original source ↗Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections